Skip to content

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

News

Select Year
Clinical Trials
Search …

December 7, 2023

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

November 3, 2023

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

November 21, 2022

Oncolytics Biotech^® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

May 4, 2022

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

May 2, 2022

Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting

April 12, 2021

Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study

April 5, 2021

Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors

March 10, 2021

Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting

December 9, 2020

Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium

November 17, 2020

Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium

Page 1 of 2

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

About Us
Leadership
Scientific Advisors
Careers
Contact

Science

Our Science
Pipeline
Publications

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Sitemap Manage Consent

Copyright © 2025 Oncolytics Biotech Inc.